Latest news with #Pyrukynd
Yahoo
10-07-2025
- Business
- Yahoo
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last?
Agios Pharmaceuticals AGIO shares ended the last trading session 7.7% higher at $39.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.1% gain over the past four weeks. This increase is due to positive investor sentiment toward the stock. A regulatory filing is currently under the FDA's review, seeking label expansion for its sole-marketed drug, Pyrukynd, across all thalassemia subtypes. A final decision is expected by Sept. 7. If approved, it will likely benefit non-transfusion-dependent patients since there is currently no approved marketed therapy for this patient population. This biopharmaceutical company is expected to post quarterly loss of $1.74 per share in its upcoming report, which represents a year-over-year change of -3%. Revenues are expected to be $9.23 million, up 7.2% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For Agios Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AGIO going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Agios Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. Phathom Pharmaceuticals, Inc. PHAT, another stock in the same industry, closed the last trading session 3.9% higher at $9.37. PHAT has returned 0.6% in the past month. Phathom Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.76. Compared to the company's year-ago EPS, this represents a change of +39.2%. Phathom Pharmaceuticals currently boasts a Zacks Rank of #2 (Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16-06-2025
- Business
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-06-2025
- Business
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
15-02-2025
- Business
- Yahoo
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank
Scotiabank lowered the firm's price target on Agios Pharmaceuticals (AGIO) to $74 from $75 and keeps an Outperform rating on the shares. The firm is impressed by the company's regulatory and clinical execution in Q4, the analyst tells investors. Scotiabank believes Agios is well-equipped to accelerated growth of the Pyrukynd franchise and remains cautiously optimistic on mitapivat's point of sickening. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on AGIO: Agios Pharmaceuticals Reports Strong 2024 Financial Results Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress Agios Pharma: Promising Growth with Strategic Market Expansion and Pipeline Advancements Agios Pharmaceuticals reports Q4 revenue $10.7M, consensus $9.35M Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study Sign in to access your portfolio
Yahoo
14-02-2025
- Business
- Yahoo
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
Net Pyrukynd Revenue (Q4 2024): $10.7 million, a 51% increase from $7.1 million in Q4 2023. Cost of Sales (Q4 2024): $1.3 million. R&D Expenses (Q4 2024): $82.8 million, an increase of $5.3 million from Q4 2023. SG&A Expenses (Q4 2024): $51.7 million, an increase of $16.4 million from Q4 2023. Cash Equivalents and Marketable Securities (End of Q4 2024): Approximately $1.5 billion. Milestone Payments (2024): Total of $1.1 billion, including $905 million from Royalty Pharma and $200 million from Servier. Warning! GuruFocus has detected 4 Warning Signs with AGIO. Release Date: February 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Agios Pharmaceuticals Inc (NASDAQ:AGIO) reported a 51% increase in net Pyrukynd revenue for Q4 2024 compared to the same quarter in 2023. The company is preparing for two additional commercial launches, with potential approval and launch of Pyrukynd in thalassemia expected in September 2025 and in sickle cell disease in 2026. Agios has a robust early and mid-stage pipeline poised for clinical advancement, including the completion of enrollment in the phase 3 rise up study for sickle cell disease. The company has a strong balance sheet with approximately $1.5 billion in cash, equivalents, and marketable securities, providing financial independence for future growth. Agios announced positive top-line results from the Activate Kids Phase 3 trial of Mitapivat in pediatric patients with PK deficiency, marking its first pediatric clinical program for a rare hemolytic anemia. Agios Pharmaceuticals Inc (NASDAQ:AGIO) expects flat revenues for PK deficiency in 2025 compared to 2024, indicating limited growth in this area. The company noted that Q4 2024 revenues were higher due to year-end stocking and adjustments, which are not expected to repeat in Q1 2025. There are concerns about liver toxicity in the sickle cell trial, leading to changes in the monitoring protocol. The launch in the Gulf region, particularly Saudi Arabia, is expected to take time due to the need for formulary access and healthcare system navigation. Agios faces challenges in pediatric development, which is complex and requires significant logistical considerations. Q: What is Agios Pharmaceuticals' strategy for updating the investment community on the safety profile of Mitapivat, especially concerning hepatocellular injury? A: Sarah Gheuens, Chief Medical Officer, stated that if there are any changes to the safety profile of Mitapivat, the company will update the investment community as they have done in the past when new safety information became available. Q: How does Agios Pharmaceuticals view the peak sales potential for Mitapivat in thalassemia and sickle cell disease? A: Brian Goff, CEO, expressed confidence in the multi-billion-dollar potential of Pyrukynd, citing the significant unmet need in thalassemia, where two-thirds of the U.S. patient population has no approved therapy, and the high unmet need in sickle cell disease, which has increased due to limitations in available therapeutic options. Q: What changes were made to the sickle cell trial protocol following the liver toxicity disclosure? A: Sarah Gheuens explained that monitoring for liver enzymes was already part of the core period of trials. The open-label extension (OLE) portion was adjusted to align with the core period's monthly monitoring for the first six months of exposure. Q: How does Agios Pharmaceuticals plan to approach the development of Tepapivat in sickle cell disease? A: Brian Goff and Tsveta Milanova, Chief Commercial Officer, indicated that they are building a sickle cell disease franchise with both Pyrukynd and Tepapivat. The development path will be guided by data from ongoing studies, and they aim to provide multiple treatment options for this complex disease. Q: How should investors model the launch trajectory for Mitapivat in thalassemia, considering potential pent-up demand? A: Tsveta Milanova noted that while there is a focus on educating and increasing urgency among physicians, they do not expect an initial bolus of patients. The launch will target about 65% of the U.S. thalassemia patient population, capturing patients as they visit their doctors. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
